Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

January 11, 2021January 14, 2021

Parents, Lacking Information, Wary of Gene Therapies, UK Survey Finds

News

Parents of children with hemophilia in the U.K. are generally aware of gene therapy, but many lack both the knowledge necessary for an informed decision and confidence regarding this form ... Read more

November 9, 2020November 9, 2020

Scientists Identify New Genetic Mutations Underlying Hemophilia A

News

Using a combination of genetic and functional approaches, scientists have identified new mutations in parts of the F8 gene that do not code for factor VIII (FVIII) in a ... Read more

November 4, 2020November 4, 2020

Hemophilia Treatments Should Be Open to All, Regardless of Cost, ICER Told

News

The full range of hemophilia treatments should be made available to patients without consideration of cost or other barriers, leaders of patient associations and others argued at a public meeting hosted ... Read more

October 30, 2020October 30, 2020

Acupuncture Might Work Better Than TENS to Reduce Chronic Joint Pain

News

Acupuncture was found to be more effective for reducing chronic joint pain in hemophilia patients than transcutaneous electrical nerve stimulation, or TENS, the results from a small clinical trial ... Read more

October 26, 2020October 26, 2020

Hemlibra Improves Quality of Life in Children With Hemophilia A, Data Show

News

Preventive treatment with Hemlibra (emicizumab) improves health-related quality of life (HQRoL) in children with hemophilia A who develop inhibitors, or neutralizing antibodies, against engineered factor VIII (FVIII), an essential ... Read more

September 28, 2020September 28, 2020

Esperoct Effective Over Long Term in Children With Severe Hemophilia A, Phase 3 Results Show

News

Long-term treatment with Esperoct (turoctocog alfa pegol) prevented bleeding in one-fifth of children with severe hemophilia A over the course of a Phase 3 clinical trial, according to final ... Read more

September 25, 2020September 25, 2020

‘Advancements’ TV Show to Feature State-of-the-Art Research in Bleeding Disorders

News

An upcoming episode of the TV series “Advancements,” hosted by Ted Danson, will be dedicated to current and future research and therapeutics for inheritable bleeding disorders. The new episode ... Read more

August 19, 2020August 19, 2020

National Hemophilia Foundation Offering Grants to Bleeding Disorder Groups

News

The National Hemophilia Foundation (NHF) has opened a grant program to support the local groups and chapters that work with bleeding disorder families, and have watched as their revenue ... Read more

August 5, 2020August 5, 2020

FVIII Prophylaxis Early in Life Improves Joint Outcomes in Hemophilia A, Study Shows

News

Starting factor VIII (FVIII) preventive therapy before the age of 2.5 years improves joint outcomes in young adults with hemophilia A compared to starting treatment later in childhood, a ... Read more

June 17, 2020June 17, 2020

DalcA Shows Sustained Efficacy in Hemophilia B in Trial

News

Under-the-skin, preventive treatment with Dalcinonacog alfa (DalcA) led to sustained and protective levels of factor IX (FIX) in people with severe hemophilia B, final data from a Phase 2b trial ... Read more